Laird J
Scottish National Blood Transfusion Service, West of Scotland Blood Transfusion Centre, Glasgow, UK.
Transfus Med. 2006 Jun;16(3):204-5. doi: 10.1111/j.1365-3148.2006.00670.x.
Anaemia is a common side-effect of malignancy and cancer therapy. Both red cells and erythropoietin will improve anaemia; however, the scarcity and risks of allogeneic blood transfusion need to be carefully considered against the expense and benefits of recombinant human erythropoietin. Both treatment options have significant economic implications and the definitive evaluation from NICE must be awaited with much interest.
贫血是恶性肿瘤和癌症治疗常见的副作用。红细胞和促红细胞生成素均可改善贫血；然而，相对于重组人促红细胞生成素的费用和益处，必须仔细权衡异体输血的稀缺性和风险。两种治疗方案都有重大的经济影响，人们满怀期待地等待英国国家卫生与临床优化研究所（NICE）的最终评估。
